Actively Recruiting
Post-Marketing Surveillance of Breztri Safety and Effectiveness in Korean Patients with COPD and Asthma
Led by AstraZeneca · Updated on 2026-09-23
600
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of Breztri in real-world clinical practice among patients diagnosed with Chronic Obstructive Pulmonary Disease COPD or asthma in Korea. This open-label, single-arm, multicenter observational study aims to confirm known safety outcomes and identify any new adverse drug reactions. It also seeks to generate clinical evidence from a diverse group of Korean patients representative of everyday medical care. Patients who start treatment with Breztri following approved indications in Korea will be enrolled and observed for up to 24 weeks. The study allows physicians to prescribe other necessary medications as part of routine care. Patient visits and follow-up schedules are determined based on clinical need, with approximately 600 patients expected across about 30 study sites. Participants will be monitored for adverse events, serious adverse events, and unexpected reactions during the 24-week period or until treatment ends if discontinued earlier. Clinical outcomes will be assessed at baseline, 12 weeks, and 24 weeks, including changes in COPD Assessment Test scores. Researchers will also explore patient baseline factors related to safety and outcomes. No additional follow-up occurs if exclusion criteria appear after enrollment.
CONDITIONS
Brief Title
BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREA
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here